Quest Diagnostics Inc (NYSE:DGX) Institutional Investor Sentiment

August 24, 2017 - By Vivian Currie

 Quest Diagnostics Inc (NYSE:DGX) Institutional Investor Sentiment

Sentiment for Quest Diagnostics Inc (NYSE:DGX)

Quest Diagnostics Inc (NYSE:DGX) institutional sentiment increased to 1.1 in 2016 Q4. Its up 0.18, from 0.92 in 2016Q3. The ratio is positive, as 242 hedge funds opened new and increased equity positions, while 220 cut down and sold their positions in Quest Diagnostics Inc. The hedge funds in our partner’s database now possess: 117.50 million shares, up from 116.81 million shares in 2016Q3. Also, the number of hedge funds holding Quest Diagnostics Inc in their top 10 equity positions increased from 3 to 4 for an increase of 1. Sold All: 41 Reduced: 179 Increased: 163 New Position: 79.

Quest Diagnostics Incorporated is a well-known provider of diagnostic information services. The company has market cap of $14.58 billion. The Firm operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. It has a 21.37 P/E ratio. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks , health plans, employers and accountable care organizations (ACOs).

About 135,524 shares traded. Quest Diagnostics Inc (NYSE:DGX) has risen 39.04% since August 24, 2016 and is uptrending. It has outperformed by 22.34% the S&P500.

Healthcor Management L.P. holds 5.84% of its portfolio in Quest Diagnostics Inc for 1.13 million shares. Randolph Co Inc owns 234,150 shares or 4.41% of their US portfolio. Moreover, Financial Advantage Inc. has 3.87% invested in the company for 46,389 shares. The Rhode Island-based Weybosset Research & Management Llc has invested 2.49% in the stock. Stellar Capital Management Llc, a Arizona-based fund reported 27,911 shares.#img1#

Since January 1, 0001, it had 0 insider purchases, and 4 sales for $2.59 million activity.

Quest Diagnostics Inc (NYSE:DGX) Ratings Coverage

Ratings analysis reveals 44% of Quest Diagnostics’s analysts are positive. Out of 18 Wall Street analysts rating Quest Diagnostics, 8 give it “Buy”, 2 “Sell” rating, while 8 recommend “Hold”. The lowest target is $68 while the high is $12300. The stock’s average target of $101.94 is -4.61% below today’s ($106.87) share price. DGX was included in 37 notes of analysts from August 4, 2015. The company was maintained on Tuesday, July 25 by Canaccord Genuity. Mizuho downgraded the shares of DGX in report on Wednesday, August 31 to “Neutral” rating. RBC Capital Markets maintained Quest Diagnostics Inc (NYSE:DGX) on Friday, October 23 with “Sector Perform” rating. Mizuho upgraded Quest Diagnostics Inc (NYSE:DGX) on Tuesday, January 3 to “Buy” rating. The rating was initiated by Citigroup on Friday, September 9 with “Neutral”. The firm earned “Buy” rating on Monday, June 26 by Raymond James. The stock has “Buy” rating by Bank of America on Tuesday, July 25. The stock of Quest Diagnostics Inc (NYSE:DGX) has “Sell” rating given on Friday, June 24 by Jyske Bank. The firm has “Buy” rating by Mizuho given on Wednesday, April 26. The stock of Quest Diagnostics Inc (NYSE:DGX) has “Hold” rating given on Tuesday, August 18 by Zacks.

More notable recent Quest Diagnostics Inc (NYSE:DGX) news were published by: which released: “Sonora Quest Laboratories Partners with CarePayment to Help Patients Pay for …” on August 16, 2017, also with their article: “Quest Diagnostics Enters Oversold Territory” published on August 18, 2017, published: “Walmart To Partner With Quest Diagnostics To Offer In-Store Lab Work” on June 27, 2017. More interesting news about Quest Diagnostics Inc (NYSE:DGX) were released by: and their article: “Quest Diagnostics considering lab in Regency Wal-Mart” published on August 22, 2017 as well as‘s news article titled: “Could Quest Diagnostics Inc (DGX) Be The Last Remaining Undervalued Stock?” with publication date: May 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.